First Trust's 30-stock strategy delivered 53.2% returns over one year, but comes with higher concentration risk and a steeper 11-basis-point fee.

For a biotech, your intellectual property is your most prized asset. | For a biotech, your intellectual property is your most ...

Novo Nordisk and Vivani Medical are testing a small implant that releases semaglutide over several months, potentially ...

When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was ...

Your hard-earned money would be better spent elsewhere.

Federal investigators say that a Chinese drug manufacturer, previously on the Food and Drug Administration’s list of preapproved foreign companies allowed to import GLP-1 ingredients, was able to ...

Warframe Tau, revealed at TennoCon 2026, adds a parallel second solar system to Digital Extremes’ long-running free-to-play ...

Vermont Business Magazine BETA Technologies, Inc. (BETA) (NYSE: BETA), an aerospace and defense company, and the Multistate ...

Ascendis Pharma stock has climbed 24.0% over the past month, yet the current valuation checks and market multiples point to a ...

Altering the risk-reward equation will inevitably affect investors’ decisions about backing Australian startups.

A letter, signed by 12 technology industry leaders and sent to the treasurer, warns the proposed CGT concessions will stifle ...

Hisar: Sirsa police have arrested another key accused in the high-profile seizure of over 3 lakh Tapentadol tablets, valued ...